Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18986129 | 1.00 | KDM4E (0.46) | KDM4ETDP1ALDH1A1MEN1HTT | |
| SCHEMBL17187391 | 0.94 | HPGD (0.38) | KDM4ETDP1ALDH1A1MEN1HTT | |
| SCHEMBL17187389 | 0.94 | HPGD (0.38) | KDM4ETDP1ALDH1A1MEN1HTT | |
| SCHEMBL19971131 | 0.89 | KDM1A (0.46) | ALDH1A1MEN1KMT2AKDM1A | |
| SCHEMBL13380623 | 0.89 | KDM1A (0.46) | ALDH1A1MEN1KMT2AKDM1A | |
| SCHEMBL22068794 | 0.87 | KDM1A (0.44) | ALDH1A1KDM1A | |
| SCHEMBL20185667 | 0.85 | KDM1A (0.43) | ALDH1A1KDM1A | |
| SCHEMBL20185675 | 0.84 | EPHX1 (0.41) | KDM4EALDH1A1KDM1APAOX | |
| SCHEMBL22068805 | 0.83 | EPHX1 (0.37) | ALDH1A1KDM1A | |
| SCHEMBL19971140 | 0.81 | CYP2C19 (0.40) | MEN1KMT2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795649-A2 | CATALYST WITH POLYSILOXANE STRUCTURE UNIT FOR CURABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2021-03-24 | — | — | EP | disclosed |
| US-10836868-B2 | Catalyst having a polysiloxane structural unit for hardenable compositions | SIKA TECHNOLOGY AG (CH) | 2020-11-17 | — | — | US | disclosed |
| US-10414875-B2 | Catalyst containing guanidine groups | SIKA TECHNOLOGY AG (CH) | 2019-09-17 | — | — | US | disclosed |
| US-20180327549-A1 | CATALYST HAVING A POLYSILOXANE STRUCTURAL UNIT FOR HARDENABLE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2018-11-15 | — | — | US | disclosed |
| US-20180148545-A1 | CATALYST CONTAINING GUANIDINE GROUPS | SIKA TECHNOLOGY AG (CH) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414875-B2 | Catalyst containing guanidine groups | GMPS, GMNN, RNMT | KDM4E 998/4885TDP1 434/4885ALDH1A1 289/4885 |
| US-20180148545-A1 | CATALYST CONTAINING GUANIDINE GROUPS | GMPS, RNMT, GMNN | KDM4E 1003/4885TDP1 271/4885ALDH1A1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.